Modern biologics discovery demands speed, precision, and scalability. In this case study, Creative Biolabs demonstrates how its High-Throughput (HTP) Recombinant Antibody Production Platform enabled a global biopharma client to generate 40+ recombinant antibody variants within just four weeks—dramatically expediting their lead optimization and de-risking development.

Inside This Case Study

• Integrated Gene-to-Antibody Workflow: Seamless transition from sequence design to milligram-scale antibody expression using transient CHO and HEK293 systems.
• High Yield & Consistency: Parallel production of hundreds of antibodies (IgG, Fab, scFv, bispecifics) under uniform, controlled conditions, ensuring batch-to-batch reproducibility.
• Therapeutic-Grade Quality: Each antibody achieved >90% purity (SEC-HPLC, SDS-PAGE) and low endotoxin levels, ready for direct use in functional assays and in vivo studies.
• Validated Results: The client’s panel exhibited robust binding performance and structural stability, verified through ELISA and SEC-HPLC analysis.

Why It Matters

The case highlights how Creative Biolabs’ automated HTP production system bridges early discovery and preclinical development—offering milligram-scale, quality-controlled antibodies in 4–5 weeks, with comprehensive format flexibility (IgG, Fab, scFv, bispecifics).

Key Outcomes

• 40+ recombinant antibody variants produced in parallel
• Consistent purity and high-concentration formulation
• Substantial acceleration of the lead optimization phase

Ready to Learn How?

Download the full case study to explore how Creative Biolabs’ HTP recombinant antibody production platform can advance your discovery pipeline with unmatched speed, quality, and scalability.